🔴 Nurix Therapeutics is trading 29.16% down in pre-market after Sanofi ended development of STAT6 degrader SAR448272

Nurix Therapeutics is trading at $18.29, down 29.16%, after Sanofi discontinued the Phase 1 trial and terminated development of SAR448272, an oral STAT6 degrader.

• Nurix will no longer be eligible for future milestone payments or royalties tied to SAR448272; other Sanofi-licensed programs remain eligible.
• Reuters and Dow Jones reported a sharp extended-hours drop following the announcement.
• The company said its $1.1 billion cash position and cash-runway guidance are unchanged.